Abstract
Therapeutic vaccines against cancer are at their prime, owing to our comprehensive understanding of immune effector responses generated against tumor and the mechanisms employed by the progressing tumor to evade the immune system. The immune system is primed by tumor-associated antigens (TAA) that are perceived as foreign. Therefore, the identification of TAA led to the development of subunit vaccine formulations comprising defined TAA as stand-alone vaccines or in combination with immune adjuvants. Inasmuch as cancer cells express a diverse set of TAA, novel immunomodulatory approaches that not only use tumor cells as a source of diverse TAA but also convert them into competent antigen-presenting cells have significant therapeutic potential as cell-based vaccines. Toward this end, we have developed a novel protein display approach designated as ProtEx™ as a safe and efficient alternative to DNA-based gene expression to generate novel immunomodulatory molecules and display them on tumor cells for the development of cancer vaccines. This chapter describes the ProtEx™ technology and its application to the generation of tumor cell-based cancer vaccines.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berzofsky JA et al (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113: 1515–1525
Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3: 630–641
Platsoucas CD et al (2003) Immune responses to human tumors: development of tumor vaccines. Anticancer Res 23:1969–1996
Dougan M, Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27:83–117. doi:10.1146/annurev.immunol.021908.132544
Schlom J (2012) Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 104:599–613
Keenan BP, Jaffee EM (2012) Whole cell vaccines—past progress and future strategies. Semin Oncol 39:276–286
Hazelbag S et al (2002) Transforming growth factor-beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum Pathol 33:1193–1199
Terabe M, Berzofsky JA (2004) Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16:157–162
Srivastava AK et al (2012) Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. PLoS One 7:e48463
Ochsenbein AF et al (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058–1064
Antonia SJ et al (2004) Current developments of immunotherapy in the clinic. Curr Opin Immunol 16:130–136
Pardoll DM (2002) Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2:227–238
Gimmi CD et al (1993) Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 90:6586–6590
Anderson RC et al (2007) Lack of B7 expression, not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas. Neurosurgery 60:1129–1136
Azuma M et al (1993) B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366: 76–79
Allison JP, Krummel MF (1995) The Yin and Yang of T cell costimulation. Science 270: 932–933
Grossman Z et al (2004) Concomitant regulation of T-cell activation and homeostasis. Nat Rev Immunol 4:387–395
Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4:336–347
Singh NP et al (2003) A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Res 63:4067–4073
Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368–370
Antonia SJ et al (2002) Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 167:1995–2000
Horig H et al (2000) Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 49:504–514
Kaech SM et al (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2:251–262
Yolcu ES et al (2011) Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing T regulatory cells in mice. J Immunol 187: 5901–5909
Sharma RK et al (2010) Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy. Cancer Gene Ther 17:730–741
Yolcu ES et al (2008) Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein. J Immunol 181: 931–939
Yolcu ES et al (2002) Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 17:795–808
Askenasy N et al (2003) Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation 107:41–47
Singh NP et al (2006) Primary tumor cells from cancer patients decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T-cell immune responses ex vivo. Hum Gene Ther 17:334–346
Pearl-Yafe M et al (2007) Fas-ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and non-immunogenic interactions. Stem Cells 25(6): 1448–1455
Acknowledgement
This study was funded in parts by Kentucky Lung Cancer Research Program, the W.M. Keck Foundation, and the Commonwealth of Kentucky Research Challenge Trust Fund.
Conflict of interest disclosure: The ProtEx™ technology described herein is licensed from University of Louisville by ApoVax, Inc. for which H. Shirwan serves as CSO and Member of the Board, and H. Shirwan and E.S. Yolcu have significant financial interest in the Company. All the other authors declare no conflicts of interest.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Shirwan, H., Yolcu, E.S., Sharma, R.K., Zaho, H., Grimany-Nuno, O. (2014). The Direct Display of Costimulatory Proteins on Tumor Cells as a Means of Vaccination for Cancer Immunotherapy. In: Lawman, M., Lawman, P. (eds) Cancer Vaccines. Methods in Molecular Biology, vol 1139. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0345-0_23
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0345-0_23
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0344-3
Online ISBN: 978-1-4939-0345-0
eBook Packages: Springer Protocols